Referencias

1- Harpaz R et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of Herpes Zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30.

2- Mueller NH et al. Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis of Disease and Latency. Neurologic Clinics. 2008;26;675-697.

3- Mueller NH et al. Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis of Disease and Latency. Neurologic Clinics. 2008;26;675-697.

4- Schmader K. Clin Geriatr Med. 2007 Aug;23(3):615-32.

5- Hadley GR, Gayle JA, Ripoll J, et al. Post-herpetic Neuralgia: a Review. Curr Pain Headache Rep. 2016;20(3):17. PMID: 26879875.

6- Culebrilla | Tratamiento | Herpes zóster | CDC.

7- Grupo de Trabajo de Vacunación frente al Herpes Zóster (GT-HZ) de la Ponencia de programa y Registro de Vacunaciones. Recomendaciones de vacunación frente a Herpes Zóster [Internet].

8- Muñoz-quiles HUMAN VACCINES & IMMUNOTHERAPEUTICS 2017, VOL. 13, NO. 11, 2606–2611

9- Muñoz-Quiles C. BMC Infect Dis. 2018 May 3;18(1):203. doi: 10.1186/s12879-018-3121-x. PMID: 29724175; PMCID: PMC5934818. . Forbes HJ. Neurology.2016 Jul 5;87(1):94-102. doi: 10.1212/WNL.0000000000002808 Epub 2016 Jun 10. PMID: 27287218; PMCID: PMC4932239

10- Muñoz-quiles HUMAN VACCINES & IMMUNOTHERAPEUTICS 2017, VOL. 13, NO. 11, 2606–2611

11- Erskine N, Tran H, Levin L, Ulbricht C, Fingeroth J, Kiefe C, Goldberg RJ, Singh S. A systematic review and meta-analysis on herpes zoster and the risk of cardiac and cerebrovascular events. PLoS One. 2017 Jul 27;12(7):e0181565. doi: 10.1371/journal.pone.0181565. PMID: 28749981; PMCID: PMC5531458.

12- https://medlineplus.gov/shingles.html


Blog

Conocé más sobre el Herpes Zóster.

Activemosantes de que el virus se reactive

¿Ya consultaste con tu médico o médica sobre el Herpes Zóster?